Arthur Allen

Visit kff.org to read Arthur's bio.

aallen@kff.org
@ArthurAllen202

The Case for Donating US Covid Vaccines Overseas

KFF Health News Original

For now, there’s not enough vaccine for the U.S., but that could change within a few months. Vaccinating other nations will be key to stopping the pandemic – and keeping it away from our shores.

‘Explained by KHN’: Consumer Concerns About the Covid Vaccines

KFF Health News Original

Our newsroom has some of the best and smartest health care and health policy reporters in the business. We’ve created a new video series — “Explained by KHN” — in which our correspondents and editors answer common health care and policy questions. In this edition we cover consumer concerns over the covid-19 vaccines.

To Extract More Doses per Vial, Vaccinators Put Squeeze on FDA to Relax Vaccine Handling Advice

KFF Health News Original

Although vaccine supply is ramping up, the supply gap puts pressure on vaccinating teams to extract every drop they can. Some are asking the FDA to waive guidance against extracting vaccine from two vials with the same needle. It’s worth a shot.

After Billions of Dollars and Dozens of Wartime Declarations, Why Are Vaccines Still in Short Supply?

KFF Health News Original

The Trump and Biden administrations both imposed wartime production requirements. But industry experts say the vast quantities of raw materials and specialty equipment needed for billions of newfangled vaccines have required herculean logistical efforts.

When Your Chance for a Covid Shot Comes, Don’t Worry About the Numbers

KFF Health News Original

The Johnson & Johnson vaccine that the FDA cleared Saturday was 66% effective overall in preventing moderate to severe covid, while the Pfizer and Moderna vaccines were more than 90% effective. But the numbers aren’t exactly comparable. And all three shots prevent hospitalization and death.

Pediatricians Want Kids to Be Part of COVID Vaccine Trials

KFF Health News Original

Some years from now, infants and school-aged children will probably be the mainstay of a universal vaccination program against COVID-19 in the United States. But first, doctors want to be sure that newfangled vaccines won’t harm them.

NIH ‘Very Concerned’ About Serious Side Effect in Coronavirus Vaccine Trial

KFF Health News Original

The AstraZeneca trial is on hold in the U.S. as scientists try to unravel whether a rare neurological condition is linked to the vaccine. But regulators are frustrated by a lack of information from the drugmaker.

LA Hospital Seeks Vaccine Trial Participants Among Its Own High-Risk Patients

KFF Health News Original

Harbor-UCLA Medical Center serves patients who are especially vulnerable to the coronavirus: They are essential workers, have chronic diseases and are members of underrepresented racial and ethnic groups. When the safety-net hospital kicks off enrollment for its COVID-19 vaccine trial Wednesday, it will look to those patients to participate.

Trust, Fear and Solidarity Will Determine the Success of a COVID Vaccine

KFF Health News Original

Polio terrified Americans, and in 1955, when Jonas Salk’s vaccine became available, they snapped it up like candy. Sixty-five years later, COVID is the latest dread virus, but many undercurrents could inhibit its acceptance.

Analysis: Get Ready For The Vaccine — They’re Never Simple

KFF Health News Original

Trials are an immense undertaking involving tens of thousands of participants. They’re likely to start this summer — but don’t expect quick results. And what’s a successful result, anyway?